Eli Lilly and Company reports results for the quarter ended September 30 - Earnings Summary

Eli Lilly and

Yesterday 13:31

Eli Lilly and Company LLY.N reported quarterly adjusted earnings of $7.48​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $7.02.  The mean expectation of twenty two analysts for the quarter was for earnings of $6.26 per share. Wall Street expected results to range from $4.65  to $9.82 per share.
Revenue rose 38.6% to $24.40 billion from a year ago; analysts expected $22.61 billion. 
Eli Lilly and Company's reported EPS for the quarter was $7.22​.
The company reported quarterly net income of $6.45 billion.
Eli Lilly and Company shares had risen by 11.3% this quarter and gained 19.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 34% in the last three months.​ 
In the last 30 days, sixteen analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 29 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Eli Lilly and Company is $1,386.50, about 7.1% above its last closing price of $1,288.30
This summary was machine generated from LSEG data October 29 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
6.26
7.48
Beat
Jun. 30 2026 
6.01
8.38
Beat
Mar. 31 2026 
6.66
8.55
Beat
Dec. 31 2025 
6.67
7.54
Beat